Long-Term Remissions With Use of High Dose Cyclophosphamide in Multiple SclerosisBilgiç AB1*, Börü UT1, Taşdemir M2, Alp SI3, Alp R4, Yıldırım S1, Duman A1, Güler N1 and Kurtzke JF5
- *Corresponding Author:
- Bilgic AB
Lütfi Kirdar Kartal Training and Research Hospital
E-mail: [email protected]
Received date: May 04, 2016; Accepted date: October 20, 2016; Published date: October 27, 2016
Citation: Bilgiç AB, Börü UT, Taşdemir M, Alp SI, Alp R, et al. (2016) Long-Term Remissions With Use of High Dose Cyclophosphamide in Multiple Sclerosis. J Mult Scler (Foster City) 3:185. doi:10.4172/2376-0389.1000185
Copyright: © 2016 Bilgiç AB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: In this study, the results of high dose intravenous monthly pulse CYC on patients with worsening relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) were evaluated. Methods: Fifty-six patients who presented with worsening RRMS (30) or SPMS (26) were to be treated with intravenous (IV) monthly pulse of 800 mg/m² CYC in the first year and bimonthly in the second year. We evaluated the results before treatment and after 12 and 24 months. Results: In the RRMS patients, after 2 years baseline EDSS had improved in 18, was unchanged in 5 and worse in 3. In RRMS group annual relapse rate was 0.92 at the beginning. it decreased to 0.23 in first year and to 0.23 in second year. The SPMS patients after 2 years baseline EDSS had improved in 5, was unchanged in 15 and worse in 3. In SPMS group annual relapse rate was 0.26 at the beggining. It decreased 0.13 in the first year and 0.04 in the second year. Conclusion: This study showed that high dose CYC treatment for two years was well tolerated and seemed effective for both RRMS and SPMS.